Last reviewed · How we verify
Ethyol
At a glance
| Generic name | Ethyol |
|---|---|
| Sponsor | Groupe Oncologie Radiotherapie Tete et Cou |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. (PHASE1, PHASE2)
- A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer (PHASE2)
- Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy (PHASE1)
- A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer (PHASE2)
- Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer (PHASE1)
- Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation (PHASE1)
- AminoMedixTM for Kidney Protection During Radionuclide Therapy
- Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethyol CI brief — competitive landscape report
- Ethyol updates RSS · CI watch RSS
- Groupe Oncologie Radiotherapie Tete et Cou portfolio CI